10-Q Filing

CARGO THERAPEUTICS, INC. CIK: 1966494 Q2 2025

Filing Information

Form Type	10-Q
Accession Number	`0000950170-25-103980`
Period End Date	20250630
Filing Date	20250806
Fiscal Year	2025
Fiscal Period	Q2
XBRL Instance	crgx-20250630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 98 Income Statement 112 Cash Flow Statement 162 Stockholders Equity 72

Balance Sheet 98 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$107.75M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$107.75M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$275.32M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$275.32M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$144.82M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$144.82M	USD	Point-in-time
Assets held for sale	`AssetsHeldForSaleNotPartOfDisposalGroupCurrent`	$479.00K	USD	Point-in-time
Assets held for sale	`AssetsHeldForSaleNotPartOfDisposalGroupCurrent`	$479.00K	USD	Point-in-time
Restricted cash	`RestrictedCashCurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashCurrent`	$567.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$5.31M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$5.31M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$4.99M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$4.99M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$345.01M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$345.01M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$258.61M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$258.61M	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$28.39M	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$28.39M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$23.48M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$23.48M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.29M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.29M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$5.31M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$5.31M	USD	Point-in-time
Total assets	`Assets`	$258.61M	USD	Point-in-time
Total assets	`Assets`	$258.61M	USD	Point-in-time
Total assets	`Assets`	$414.05M	USD	Point-in-time
Total assets	`Assets`	$414.05M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.44M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.44M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$8.67M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$8.67M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$12.52M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$12.52M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$277.00K	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$277.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$739.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$739.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$9.44M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$9.44M	USD	Point-in-time
Accrued restructuring costs	`AccruedRestructuringCosts`	$10.65M	USD	Point-in-time
Accrued restructuring costs	`AccruedRestructuringCosts`	$10.65M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$578.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$578.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$628.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$628.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.03M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.03M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$20.91M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$20.91M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$28.80M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$28.80M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$20.91M	USD	Point-in-time
Total liabilities	`Liabilities`	$20.91M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.83M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.83M	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$46.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$684.74M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$684.74M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$672.54M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$672.54M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-9.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-9.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-312.65M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-312.65M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-447.08M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-447.08M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$360.23M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$360.23M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$237.70M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$237.70M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$436.10M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$436.10M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$282.46M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$282.46M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$373.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$373.21M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$414.05M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$414.05M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$258.61M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$258.61M	USD	Point-in-time

Income Statement 112 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$7.51M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.51M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$67.96M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$67.96M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$37.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$37.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$38.15M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$38.15M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$22.16M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$22.16M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.29M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.29M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$11.86M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$11.86M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$19.80M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$19.80M	USD	2 Qtrs
Restructuring, impairment, and costs of suspended programs	`RestructuringCostsAndAssetImpairmentCharges`	$37.10M	USD	1 Quarter
Restructuring, impairment, and costs of suspended programs	`RestructuringCostsAndAssetImpairmentCharges`	$37.10M	USD	1 Quarter
Restructuring, impairment, and costs of suspended programs	`RestructuringCostsAndAssetImpairmentCharges`	$83.38M	USD	2 Qtrs
Restructuring, impairment, and costs of suspended programs	`RestructuringCostsAndAssetImpairmentCharges`	$83.38M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$90.12M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$90.12M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$49.32M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$49.32M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$52.90M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$52.90M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$141.32M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$141.32M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-90.12M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-90.12M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-49.32M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-49.32M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-52.90M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-52.90M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-141.32M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-141.32M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$9.99M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$9.99M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$7.21M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$7.21M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$4.99M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.99M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.27M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.27M	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-17.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-17.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-307.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-307.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-27.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-27.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-318.00K	USD	2 Qtrs
Other expense, net	`OtherNonoperatingIncomeExpense`	$-318.00K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-323.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-323.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-105.00K	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-105.00K	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-300.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-300.00K	USD	2 Qtrs
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-44.00K	USD	1 Quarter
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-44.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-44.39M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-44.39M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-134.74M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-134.74M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-50.04M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-50.04M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-80.48M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-80.48M	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.04	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.04	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-2.80	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-2.80	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-2.80	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-2.80	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.02	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.04	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.04	USD	1 Quarter
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.90	USD	2 Qtrs
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-1.90	USD	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	47.99M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	47.99M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	48.13M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	48.13M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.13M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.13M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	47.99M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	47.99M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	43.34M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	42.17M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	42.17M	shares	2 Qtrs

Cash Flow Statement 162 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Stock-based compensation expense	`ShareBasedCompensation`	$12.13M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$12.13M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$8.21M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$8.21M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.08M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.08M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.76M	USD	2 Qtrs
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.76M	USD	2 Qtrs
Depreciation	`Depreciation`	$40.00K	USD	1 Quarter
Depreciation	`Depreciation`	$40.00K	USD	1 Quarter
Depreciation	`Depreciation`	$600.00K	USD	1 Quarter
Depreciation	`Depreciation`	$600.00K	USD	1 Quarter
Depreciation	`Depreciation`	$712.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$712.00K	USD	2 Qtrs
Depreciation	`Depreciation`	$1.17M	USD	2 Qtrs
Depreciation	`Depreciation`	$1.17M	USD	2 Qtrs
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	$2.16M	USD	1 Quarter
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	$2.16M	USD	1 Quarter
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	$10.20M	USD	2 Qtrs
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	$10.20M	USD	2 Qtrs
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	-	USD	1 Quarter
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	-	USD	1 Quarter
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	-	USD	2 Qtrs
Impairment of long-lived assets	`ImpairmentOfLongLivedAssetsHeldForUse`	-	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$665.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$665.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$150.00K	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$150.00K	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.64M	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.64M	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$1.48M	USD	2 Qtrs
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$1.48M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-316.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-316.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$973.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$973.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-5.31M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-5.31M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-13.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-13.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.53M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.53M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.32M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.32M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$6.13M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$6.13M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$-11.72M	USD	2 Qtrs
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$-11.72M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.13M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.13M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-8.59M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-8.59M	USD	2 Qtrs
Accrued restructuring costs	`IncreaseDecreaseInAccruedRestructuringCosts`	$10.65M	USD	2 Qtrs
Accrued restructuring costs	`IncreaseDecreaseInAccruedRestructuringCosts`	$10.65M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-6.45M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-6.45M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-79.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-79.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-115.08M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-115.08M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-65.23M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-65.23M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$81.69M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$81.69M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$360.38M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$360.38M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$73.80M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$73.80M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$241.76M	USD	2 Qtrs
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$241.76M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.75M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.75M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$481.00K	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$481.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$830.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$830.00K	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$1.19M	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$1.19M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-290.17M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-290.17M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$158.40M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$158.40M	USD	2 Qtrs
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$103.27M	USD	2 Qtrs
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$103.27M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$43.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$43.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$106.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$106.00K	USD	2 Qtrs
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	2 Qtrs
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	2 Qtrs
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	2 Qtrs
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.25M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.25M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$43.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$43.00K	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-252.15M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-252.15M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$43.37M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$43.37M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$154.15M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.31M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.31M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$153.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$107.75M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$107.75M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Restricted Cash	`RestrictedCash`	$567.00K	USD	Point-in-time
Restricted Cash	`RestrictedCash`	$567.00K	USD	Point-in-time
Restricted Cash	`RestrictedCash`	$567.00K	USD	Point-in-time
Restricted Cash	`RestrictedCash`	$567.00K	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.31M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$154.15M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	2 Qtrs
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$754.00K	USD	2 Qtrs
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$754.00K	USD	2 Qtrs
In-process research and development costs in accounts payable and accrued clinical and research and development expenses	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses`	$493.00K	USD	2 Qtrs
In-process research and development costs in accounts payable and accrued clinical and research and development expenses	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses`	$493.00K	USD	2 Qtrs
Deferred issuance costs related to the private placement, included in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToThePrivatePlacementIncludedInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities`	$381.00K	USD	2 Qtrs
Deferred issuance costs related to the private placement, included in accounts payable, accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToThePrivatePlacementIncludedInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities`	$381.00K	USD	2 Qtrs

Stockholders Equity 72 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$237.70M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$237.70M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$282.46M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$282.46M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	1 Quarter
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	1 Quarter
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	17,478.00	shares	2 Qtrs
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	17,478.00	shares	2 Qtrs
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$38.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$38.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$80.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$80.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$26.00K	USD	1 Quarter
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$26.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$19.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$19.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$11.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$7.00K	USD	1 Quarter
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$7.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.30M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.30M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.90M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.90M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.88M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.88M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.26M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.26M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-84.50M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-134.44M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-49.94M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-80.16M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-44.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.81M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-44.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-44.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-105.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-105.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-195.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-195.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-279.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-279.00K	USD	1 Quarter
Ending balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$237.70M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$237.70M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$436.10M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$282.46M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$282.46M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$373.21M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.